Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

July 31, 2008

Conditions
Breast Neoplasms
Interventions
DRUG

Nanoparticle albumin bound paclitaxel followed by FEC

Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. \[or if given with trastuzumab 75 mg/m2 IV over 15 min.\]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days

Trial Locations (1)

15212

NSABP Operations Center, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

NSABP Foundation Inc

NETWORK